Endocrine, metabolic & immune disorders drug targets · 2026
Effects of Intraperitoneal Colchicine on the Metabolic Consequences of High Fat Diet-Induced Obesity in Mice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lyman Alexa P, Levine Jordan A, Arner Brooke E, Stearns Blaise, Patel Tushar P, Demidowich Andrew P, Blank Paul S, Zimmberberg Joshua J, Yanovski Jack A
Аннотация
INTRODUCTION: Obesity-associated inflammation promotes metabolic dysregulation and insulin resistance. Colchicine, a potent microtubule inhibitor, suppresses NLRP3 inflammasome activity and acts proximally to inhibit the inflammatory pathway. The primary objective was to evaluate the impact of intraperitoneal (IP) colchicine administration on inflammation and metabolic parameters in mice with high-fat diet-induced obesity.
METHODS: C57BL/6 mice consumed a 45% fat diet from age 8 weeks to 16 weeks to induce obesity and inflammation. From weeks 12-16, 39 male and 29 female mice were randomized 1:1 to IP vehicle or IP colchicine 0.2 mg/kg/d. Glucose and insulin tolerance tests were performed, and CRP was measured to evaluate systemic inflammation. NLRP3 and Caspase-1 expression were assessed to evaluate hepatic inflammation.
RESULTS: Body weight was lower for both male and female mice administered colchicine versus placebo (p<0.001). Serum CRP decreased in colchicine vs placebo in both male and female mice (p's<0.05). However, there was no evidence to support a colchicine-induced change in hepatic NLRP3 and Caspase-1 expression. Despite attenuating weight gain, colchicine worsened whole-body insulin sensitivity during a post-treatment insulin tolerance test compared to placebo in male mice (p < 0.01).
DISCUSSION: In mice with high-fat diet obesity, IP colchicine 0.2 mg/kg for 4 weeks significantly suppressed inflammation but had no significant effect on markers of hepatic inflammasome activity. Colchicine treatment also induced considerable weight loss and worsened whole-body insulin sensitivity in male mice.
CONCLUSION: Although this dose has been used in prior short-term mouse studies to suppress inflammation, chronic administration of 0.2 mg/kg intraperitoneal colchicine appears not suitable for metabolic studies.
METHODS: C57BL/6 mice consumed a 45% fat diet from age 8 weeks to 16 weeks to induce obesity and inflammation. From weeks 12-16, 39 male and 29 female mice were randomized 1:1 to IP vehicle or IP colchicine 0.2 mg/kg/d. Glucose and insulin tolerance tests were performed, and CRP was measured to evaluate systemic inflammation. NLRP3 and Caspase-1 expression were assessed to evaluate hepatic inflammation.
RESULTS: Body weight was lower for both male and female mice administered colchicine versus placebo (p<0.001). Serum CRP decreased in colchicine vs placebo in both male and female mice (p's<0.05). However, there was no evidence to support a colchicine-induced change in hepatic NLRP3 and Caspase-1 expression. Despite attenuating weight gain, colchicine worsened whole-body insulin sensitivity during a post-treatment insulin tolerance test compared to placebo in male mice (p < 0.01).
DISCUSSION: In mice with high-fat diet obesity, IP colchicine 0.2 mg/kg for 4 weeks significantly suppressed inflammation but had no significant effect on markers of hepatic inflammasome activity. Colchicine treatment also induced considerable weight loss and worsened whole-body insulin sensitivity in male mice.
CONCLUSION: Although this dose has been used in prior short-term mouse studies to suppress inflammation, chronic administration of 0.2 mg/kg intraperitoneal colchicine appears not suitable for metabolic studies.